Roche’s Genentech Reports Positive Phase III CELESTIMO Results for Lunsumio in Follicular Lymphoma

Phase 3positiveLunsumioPositive

AI Analysis

Summary

Roche's Genentech reported positive Phase III CELESTIMO results for Lunsumio in follicular lymphoma treatment. The positive trial data represents meaningful progress in the development of this therapeutic candidate.

Clinical Trial Data

Phase

Phase III

Outcome Details

CELESTIMO Phase III trial reported positive results

Importance:7/10

Sentiment:

0.80

Phase_3_DataOncologyLymphomaClinical_Trial

Related Companies

$RHHBY

Read the original article

Published by yahoo_finance on September 17, 2026 2:25 PM

Read Original